Last checked at 20 May 2021 07:00
IXICO plc
("IXICO" or the "Company")
Phase II Alzheimer's disease contract award worth >£1m
IXICO plc (AIM:IXI), the AI data analytics company delivering insights in neuroscience, announces that it has been awarded an expansion contract by a current biopharmaceutical client to support the company's Phase II Alzheimer's disease clinical trial. Alzheimer's disease is a progressive degenerative disease affecting approximately 50 million people worldwide with devastating physical, emotional and financial impact to patients and families.
Conducted across 125 sites in 10 countries, the clinical trial will investigate efficacy, safety and tolerability of an anti-Tau antibody treatment for individuals with prodromal and mild Alzheimer's disease. For the study, IXICO will provide advanced neuroimaging solutions involving structural magnetic resonance imaging (MRI), volumetric MRI (vMRI), diffusion MRI (dMRI) and arterial spin labelling (ASL).
The study is worth in excess of £1m over five years.
Lammert Albers, Chief Commercial Officer of IXICO, commented: "IXICO is delighted to be awarded the contract for this Alzheimer's disease clinical trial. With no available therapies to address the underlying disease pathology, Alzheimer's disease remains a critical area of unmet medical need, and we are proud to support sponsors in their tireless efforts to bring potential treatments for this devastating disease."
For further information please contact:
IXICO plc | +44 (0)20 3763 7498 | |||
Giulio Cerroni, Chief Executive Officer Grant Nash, Chief Financial Officer |
| |||
| ||||
Cenkos Securities PLC (Nominated adviser and sole broker) | +44 (0)20 7397 8900 | |||
Giles Balleny / Max Gould (Corporate Finance) |
| |||
Michael F Johnson / Russell Kerr (Sales |
| |||
| ||||
Walbrook PR Ltd | +44 (0)20 7933 8780
| |||
Paul McManus / Lianne Cawthorne / | IXICO@walbrookpr.com | |||
Alice Woodings
| ||||
About IXICO
IXICO is dedicated to delivering insights in neuroscience. Our purpose is to advance medicine and human health by turning data into clinically meaningful information, providing valuable new insights in neuroscience and our goal is to be a leading proponent of artificial intelligence in medical image analysis. We will achieve this by developing and deploying breakthrough data analytics, at scale, through our remote access technology platform, to improve the return on investment in drug development and reduce risk and uncertainty in clinical trials for our pharmaceutical clients.
More information is available on www.IXICO.com and follow us on Twitter @IXICOnews